PodcastIntel
Sign in Get Started Free
Urology Times

Matthew Galsky, MD, on how EV/pembrolizumab is redefining the MIBC treatment paradigm

Jul 29, 2026 · 0:03:33
Listen to Episode
✨ AI Summary
  • EV/pembrolizumab redefines the MIBC treatment paradigm.
  • Moving beyond cisplatin eligibility for MIBC treatment.
  • Influences future approaches to surgery and therapy.

Guests on This Episode

MM
Matthew Galsky, MD
1 podcast appearance

More from Urology Times

The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
Aug 21, 2026 · 0:08:32
Kari Tikkinen, MD, PhD, discusses POISE-3 findings on tranexamic acid in urologic surgery
Aug 21, 2026 · 0:04:55
Expert APProach: Advancing APP Leadership & Expertise in Urology, With Susanne Quallich, PhD, ANP-BC
Aug 20, 2026 · 0:28:10
Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer care
Aug 20, 2026 · 0:02:47
View all episodes →

Get AI Summaries for Every New Episode

Subscribe to Urology Times and get AI summaries, guest tracking, and email digests delivered automatically.

Sign Up Free →